Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review by Dillon, P. et al.
Regression of advanced melanoma upon withdrawal of
immunosuppression: case series and literature review
P. Dillon,
The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 130
Manning Dr, CB 7305, Chapel Hill, NC 27516, USA
N. Thomas,
Department of Dermatology, The University of North Carolina at Chapel Hill, 130 Manning Dr, CB
7305, Chapel Hill, NC 27516, USA
N. Sharpless, and
The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 130
Manning Dr, CB 7305, Chapel Hill, NC 27516, USA
F. Collichio
The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 130
Manning Dr, CB 7305, Chapel Hill, NC 27516, USA
P. Dillon: pdillon@unch.unc.edu
Abstract
We report two cases of stage IV malignant melanoma arising in patients treated with azathioprine
for myasthenia gravis. In both cases, the melanoma metastases regressed upon withdrawal of
immunosuppression. One patient remains melanoma free at 10 years, and the second patient
experienced an 18-month disease free period. There is one prior case report in the medical
literature to support full immune reconstitution for treatment in advanced immunosuppression-
related melanoma, and one case series suggesting that transplant patients developing melanoma
may benefit from a switch to sirolimus. Virtually, no data exist for the medical management of
early stage melanoma in the immunosuppressed patients. We review the limited preclinical data in
support of immune reconstitution and the data on immunosuppression as a risk factor for
melanoma. We conclude that reduction or withdrawal of immunosuppression may be beneficial in
patients with advanced stage melanoma and warrants further consideration in patients with early
stage melanoma.
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Introduction
Advanced melanomas arising in immunosuppressed patients are rare. Efforts to define the
etiologic association between melanoma and immunosuppression have previously been
hindered by low incidence rates and conflicting results in different patient subsets. For
treatment of immunosuppression-related melanomas, there is little data for stage IV disease
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and none in early stage disease. There is also no data to stratify risk for melanoma survivors
starting immunosuppression. We report two remarkable cases of melanoma regression upon
immune reconstitution and suggest a treatment paradigm for immunosuppression-related
melanomas. We review the literature on immunosuppression and melanoma, which is
primarily limited to defining the etiologic association between the two.
Case 1
A 62-year-old Caucasian with history of Guillan-Barre, polymyositis and myasthenia gravis
was diagnosed with cutaneous melanoma of the scalp in 1998. The melanoma had a Breslow
depth of 4 mm, with ulceration and a negative sentinel lymph node. The patient had been
treated with prednisone and azathioprine intermittently for 10 years, and he was on
azathioprine at the time of melanoma diagnosis. Eight months after primary resection, the
patient developed a PET avid 5-mm lesion in the thymus and multiple PET avid lung
nodules. He underwent surgical excision of the thymus and one of the lung nodules.
Pathology revealed metastatic melanoma in the thymus and lung. Following thymectomy,
the azathioprine was tapered off over 3 months. The patient had no recurrence of myasthenia
symptoms off azathioprine suggesting that the thymectomy may have been curative of the
myasthenia. The pulmonary metastases completely resolved within 6 months. The patient
continued on close surveillance and is now at 10 years from diagnosis of stage IV disease
with no evidence for disease recurrence. The patient continues to work at the age of 72.
Case 2
A 65-year-old Caucasian male with history of myasthenia gravis treated with azathioprine
for 11 years was diagnosed with melanoma in 2006. At diagnosis of melanoma, the tumor
was Breslow depth 3.45 mm with a positive sentinel node and negative completion lymph
node dissection. The patient was not treated with interferon due to the myasthenia. Five
months after diagnosis, the patient developed in-transit metastases in the neck and scalp and
was treated with wide local excision. Three months later, a second local recurrence was
found, but was deemed unresectable due to nerve sheath involvement in the neck. The
patient was treated with radiation therapy at a dose of 48 gray with good local response.
Four weeks after completion of radiation, multiple new skin deposits were found on the back
with largest measuring 4.1 cm. In coordination with neurology, the azathioprine was tapered
off. The patient tolerated discontinuation of immunosuppression and was maintained with
mestinon for myasthenia symptoms. At 8 weeks off azathioprine, most of the tumors had
disappeared completely and the remaining back mass had decreased to 0.3 cm. At 5 months
off azathioprine, there was no measurable metastatic disease by examination nor by PET/CT
scan. The patient remained melanoma free for 18 months, before a recurrence in a bone site
was found. The patient declined further interventions and succumbed to the disease another
12 months later.
Discussion
The link between post-transplant immunosuppression and leukemia/lymphoma is well
established [1], but solid tumor incidence post-transplant remains debatable (Table 1). For
melanoma, organ transplant recipients have been reported to have incidences of two to
ninefold higher than the general population [2-10]. The post-transplant melanomas arise on
average 36 months post-transplant and tend to be deeper and worse stage at diagnosis than
melanomas in the general population, despite skin surveillance protocols within many
transplant programs [11].
In a meta-analysis of 13 transplant studies including 73,284 patients, melanomas occurred
1.6–2.5 times more commonly in transplant patients than in the general population. The
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highest melanoma risk seen in any population to date was a renal transplant cohort of 1,874
patients followed in the United Kingdom (UK). In this cohort, 12 incident melanomas were
observed, which was a rate eight times the standardized rate for the UK at that time [2]. In
Australia, the standardized incidence ratio of melanoma following kidney transplant was
3.18 (95% CI 2.75–3.67) among 13,077 patients transplanted between 1980 and 2003 [12].
In a retrospective renal transplant cohort from Queensland from 1969 to 1994, the relative
risk of developing melanoma post-transplant was 2.0 (N = 1098) [13]. It is notable that
Australia has among the highest melanoma rates in the world, so the elevated post-transplant
melanoma rate may not represent the rates in other parts of the world. In fact, a Swedish trial
of 5,356 solid-organ transplant recipients between 1970 and 1994 found no increased
melanoma rate despite an average 5-year follow-up [14].
Mirroring the solid-organ transplant experience, the bone marrow transplant (BMT) studies
indicate increased secondary malignancies as well as secondary melanomas following BMT
[15-22]. Relative risks from 1.85 to 65 have been reported for melanoma post-BMT. We
caution that the heavy chemotherapy pretreatment, the high doses of radiation/chemotherapy
for marrow ablation, the variable degree of immunosuppression and the rates of graft versus
host disease in BMT may confound the relationship between melanoma and
immunocompetence in the post-BMT population.
In non-transplant immunosuppressed patients, for example patients with rheumatoid arthritis
(RA), there is an increased melanoma risk in some studies that is not replicated in all
cohorts. [23-25] One positive study cohort from Australia consisted of 459 methotrexate-
treated RA patients and found a threefold increase in melanoma risk among the
methotrexate-treated RA patients relative to the general population [26]. In the Netherlands,
a study showed no increased malignancy of any type in RA patients treated with
cyclosporine and followed for 5 years [27]. A Finnish study of 46,000 RA patients found no
melanoma risk, despite an elevated lymphoma risk [28]. In the United States, Wolfe et al.
[29] found a significantly increased risk of melanoma (OR 2.3, 95% CI 0.9–5.4) using the
US National Databank for Rheumatic Diseases, which included 13,000 subjects and 49,000
patient-years of observation.
Other autoimmune cohorts have been studied for incidence of malignancy. These include
lupus, psoriasis, Crohn’s disease, myasthenia gravis, Wegener’s and ocular disorder patients.
These studies generally had small numbers and varying degrees of correlation between
immunosuppression and melanoma. No conclusion about melanoma risk nor melanoma
treatment can be drawn from these small studies [30-33] (Table 2).
In patients with HIV, T-cell immunosuppression is induced by viral replication rather than
by immunosuppressants, but the melanoma risk is similar to transplant patients. The effect
of HIV-associated immune dysfunction is demonstrated by the frequent development HIV-
associated lymphoma, anal cancer, Kaposi sarcoma and cervical cancer. The role of HIV-
related immune dysfunction is less well established in other malignancies such as
melanoma. A number of case reports suggested a link between HIV and solid cancers, but
two larger studies have shown no statistically significant correlation between CD4 count and
solid cancer incidence [34, 35]. On the contrary, a large meta-analysis [36] looked at cancer
incidences in both transplant recipients and patients with HIV and found positive
correlations with cancer in both. The meta-analysis presented standardized incidence ratios
from seven studies of patients with HIV/AIDS (n = 444,172) and five studies of transplant
recipients (n = 31,977). For 20 of the 28 types of cancer examined, there was a statistically
significant increased cancer incidence in both populations. Melanoma had an incidence ratio
of 2.34 (1.96–2.77, 95% CI) in transplant patients and an incidence ratio of 1.24 (1.04–1.48,
95% CI) in patients with HIV. This study is compelling evidence for immune dysfunction in
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melanoma because it compares two populations that do not share lifestyle and host cancer
risk factors, yet experience similar risks for melanoma development.
Worldwide, a consensus about malignancy risks for immunosuppression is lacking. This
may be due to differing incidence rates for different solid tumors and the differing rates of
cancer in various transplant and non-transplant cohorts. In fact, a possible protective effect
may exist for tumors associated with chronic inflammation such as colon cancer, although
this has not been fully born out. Nevertheless, in the United States, the Food and Drug
Administration added a black box warning to the TNF inhibitors in August 2009 for
pediatric and adolescent use warning that increased rates of leukemia and other
malignancies are possible.
Harnessing the immune system in melanoma
The histologic finding of infiltrating lymphocytes within most melanomas suggests that
immune recognition of melanoma is important to control of disease progression.
Importantly, the tumor-infiltrating lymphocytes (TIL) have been shown to have melanoma
specificity. Furthermore, the degree of lymphocyte infiltration within a melanoma is shown
to be prognostic of melanoma progression [37]. There is a finding that approximately 10%
of patients with melanoma will develop vitiligo-like patches, known as melanoma-
associated hypopigmentation (MAH). The development of MAH is thought to represent a T-
cell-mediated attack against common melanocyte antigens also present on tumor cells. The
patients with MAH likely develop effective immunity against the malignant cells [38].
Further confirmation of T-cell specificity has been seen in the related phenomenon of
spontaneous regression in melanoma. Evidence of spontaneous regression can be seen both
clinically and histologically and is thought to be controlled by CD8+ cytotoxic T-cells [39,
40]. Just like the TIL cells, the lymphocytes from the blood of spontaneous regression
patients show T-cell specificity for melanocytes. Interestingly, there may also be a role for B
cells in melanoma. Circulating melanoma specific antibodies have been identified in similar
studies and are under further investigation [41, 42].
There is clinical evidence that the immune phenomena observed earlier can be harnessed to
treat melanoma. For example, interferon alpha treatment in stage III melanoma results in an
improved progression free survival compared to placebo [43]. The more compelling aspect
of interferon is the disproportionate difference in response among those patients who
develop signs of autoimmunity and those who do not while on interferon. The difference is a
50-fold improvement in overall survival for patients developing autoimmune phenomenon
(P < 0.001) [44]. Clinical support for immune recruitment also comes from the cytokine
IL-2, an even more potent stimulator of the immune system than interferon alpha. IL-2 acts
through promotion of proliferation, differentiation and recruitment of T and B cells, natural
killer (NK) cells and thymocytes as well as increasing the cytolytic activity of CD4 and CD8
tumor infiltrating lymphocytes. IL-2 produces a number of durable responses in stage IV
melanoma and is therefore offered for some cases of metastatic disease [45]. IL-2 shows
similarly improved efficacy in patients developing autoimmune phenomena.
A further clinical application of T-cell recruitment in melanoma was reported by Rosenberg
et al. in 2002 [46]. In their work, they showed that the re-infusion of ex vivo-expanded
tumor-infiltrating lymphocytes from advanced melanomas can result in significant tumor
reductions. In the study, 6 of 13 patients had objective clinical responses to the “adoptive
cell transfer.” Five of the responding patients demonstrated autoimmune melanocyte
destruction. Follow-up reports from the National Cancer Institute (NCI) have replicated
early findings and improved patient outcomes with the addition of a lymphocyte-depleting
pre-conditioning regimen. The adoptive cell transfer therapy has been replicated outside the
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NCI [47], confirming the potential roles for T-cell therapies in melanoma and perhaps
confirming the risks to T-cell depletion used in transplant and other immunosuppressive
regimens.
By a similar mechanism of action, melanoma vaccine work has shown that the immune
system can be re-programmed to recognize aberrant melanoma cells. The basic melanoma
vaccine approach involves subcutaneous injection of known melanoma proteins with an
adjuvant, with the goal of stimulating melanoma specific T cells. A number of reports have
suggested potential roles for melanoma vaccines, but to date, no vaccines have reached FDA
approval [48]. Similar pharmaceutical approaches to harnessing the T cells in melanoma are
in clinical trials. For example, the CTLA4 inhibiting antibodies, which may be close to FDA
approval, are enhancers of T-cell activity and proliferation. These antibodies block the T cell
co-receptor responsible for preventing overstimulation. The ultimate effect seems to be
alteration in the balance of T effector cells in relation to T suppressor cells both within the
tumor microenvironment and distantly. The CTLA4 inhibiting antibodies have shown
positive clinical activity with manageable side effect profiles. A similar pharmaceutical
approach is to target antibodies against PD-1 (programmed death) and PD-1 ligand to
increase T-cell activity. Phase I/II trials with both types of antibodies are currently underway
and the preclinical work has shown that IL-2 production can be restored following PD-1
blockade [49].
Conclusion
The two cases discussed in this report highlight the role of T-cell function in immune
surveillance. The re-constitution of the immune system in both case reports resulted in
regression of melanoma metastases. The positive responses to immunosuppressive
withdrawal are similar to a previously published case by Hodi et al. [50] and follow the
well-established treatment paradigm for post-transplant lymphoproliferative disorders. An
additional case series of post-transplant malignancies including two melanomas suggests
that switching to sirolimus for immunosuppression may allow improved immune
surveillance without graft sacrifice [51]. In addition to the case series and anecdotal
evidence, there are plausible immunologic mechanisms to support discontinuation of
immunosuppression in the setting of advanced melanoma [52, 53]. Our experience in these
and other cases suggests that selected autoimmune-associated melanomas will benefit from
withdrawal of immunosuppression. To date, there are no randomized trials to guide
treatment in either the early or advanced melanoma patient population and as such we
recommend caution when considering a trial of immunosuppressive withdrawal.
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Table 1
Proposed mechanisms that immunosuppressants may contribute to cancer development
Mechanisms suggested for immunosuppressant-related cancers:
1 Downregulation of immune surveillance, allowing precancerous lesions to progress unchecked
2 Increased susceptibility to infection with oncogenic viruses (i.e., melanoma-associated retrovirus that was detected in murine and
human melanoma)
3 Pharmacologic effects of the immunosuppressant on DNA (alkylating agents) or DNA metabolism (antimetabolites)
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